Capital Analysts LLC’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,500
Closed -$105K 746
2020
Q3
$105K Hold
1,500
0.01% 307
2020
Q2
$109K Hold
1,500
0.01% 270
2020
Q1
$69K Hold
1,500
0.01% 294
2019
Q4
$93K Sell
1,500
-230
-13% -$12.3K 0.01% 307
2019
Q3
$73K Hold
1,730
0.01% 325
2019
Q2
$90K Hold
1,730
0.01% 288
2019
Q1
$95K Hold
1,730
0.01% 268
2018
Q4
$73K Hold
1,730
0.01% 262
2018
Q3
$121K Hold
1,730
0.01% 232
2018
Q2
$99K Hold
1,730
0.01% 248
2018
Q1
$95K Hold
1,730
0.01% 249
2017
Q4
$97K Hold
1,730
0.01% 243
2017
Q3
$106K Hold
1,730
0.01% 236
2017
Q2
$92.4K Hold
1,730
0.01% 250
2017
Q1
$83.5K Hold
1,730
0.01% 228
2016
Q4
$69K Hold
1,730
0.01% 251
2016
Q3
$83.8K Buy
+1,730
New +$82.2K 0.02% 220
2016
Q2
Sell
-1,730
Closed -$70.7K 333
2016
Q1
$70.7K Hold
1,730
0.01% 242
2015
Q4
$124K Hold
1,730
0.03% 197
2015
Q3
$101K Hold
1,730
0.02% 228
2015
Q2
$156K Hold
1,730
0.03% 187
2015
Q1
$137K Hold
1,730
0.03% 183
2014
Q4
$109K Hold
1,730
0.02% 189
2014
Q3
$89.9K Hold
1,730
0.02% 198
2014
Q2
$80.3K Hold
1,730
0.02% 197
2014
Q1
$69.1K Buy
+1,730
New +$78.5K 0.02% 204

Other funds holding BIB

Capital Analysts LLC's BIB Position: Q4 2020 in Review

Capital Analysts LLC sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2020, closing a stake of 1,500 shares — an estimated $105K sold.

Capital Analysts LLC first reported a position in BIB in Q1 2014 and held it in 26 quarters. The position peaked at $156K in Q2 2015. 34 funds tracked by Wall St. Rank hold BIB as of Q4 2020.

  • Capital Analysts LLC reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 1,500 ProShares Ultra NASDAQ Biotechnology shares in Q4 2020, an estimated $105K.
  • Capital Analysts LLC first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 26 quarters.
  • Capital Analysts LLC's ProShares Ultra NASDAQ Biotechnology position peaked at $156K in Q2 2015.
  • 34 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.